FDA Approves Novel Targeted Therapy for Metastatic Pancreatic Cancer

The FDA has granted approval to daraxonrasib (Rasonque), a RAS inhibitor, for adults with metastatic pancreatic adenocarcinoma who have undergone prior systemic therapy or are unsuitable for multiagent treatment. This marks the first RAS-directed therapy specifically approved for this aggressive cancer, offering a crucial new option for patients and potentially extending lives.